Skip to main content

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

  • The original article was published in Arthritis Research & Therapy 2020 22:115

Correction to: Arthritis Research & Therapy (2020) 22: 115

https://doi.org/10.1186/s13075-020-02199-8

Following publication of the original article [1], the authors identified errors in Fig. 1. The legends in Fig. 1c and d refer to placebo, baricitinib 4-mg and adalimumab treatment groups; the legends should refer to placebo, baricitinib 2-mg, and baricitinib 4-mg and the reference to these two studies in the figure caption are reversed. Additionally, the total number of interruptions for baricitinib 4-mg in RA-BEAM (Fig. 1b) has been corrected from 82 to 62 and the title for RA-BEAM has been corrected from 0-52 weeks to 0-24 weeks; labels have been corrected for MTX (8–14 days) in RA-BEGIN from 28 to 29 and for placebo (15–21 days) in RA-BUILD from 17 to 16.

The corrected Fig. 1 is given below.

Fig. 1
figure1

Duration of interruptions in the phase 3 studies RA-BEGIN (a), RA-BEAM (b), RA-BEACON (c), and RA-BUILD (d)a,b. aInterruptions are based on daily tablet baricitinib study drug, including in non-baricitinib groups, which represent interruptions of the matching placebo for baricitinib. bTemporary interruption is defined as a temporary withholding of study drug that is followed by resumption of study drug during the study. MTX, methotrexate

Reference

  1. 1.

    Emery P, Tanaka Y, Cardillo T, et al. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22:115. https://doi.org/10.1186/s13075-020-02199-8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Paul Emery.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Emery, P., Tanaka, Y., Cardillo, T. et al. Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Res Ther 22, 166 (2020). https://doi.org/10.1186/s13075-020-02257-1

Download citation